The standard Ontario diagnostic path for Lyme disease is two-tier serology: ELISA first, then confirmatory Western blot. The test works by detecting antibodies the patient has produced against Borrelia burgdorferi. This is the structural problem. In early-phase Lyme infection — the first two to six weeks — the immune system has not yet produced a detectable antibody load. The test is measuring for a response that hasn't happened yet. PEMCLAU V12 has indexed six peer-reviewed PMIDs confirming this, including Johnson et al. (2018) and Branda et al. (2017), which place early-phase two-tier sensitivity at 29–40%. The second problem is VlsE surface protein rotation. Borrelia's outer surface protein rotates its configuration as the infection progresses. By the time the test sample is processed, the dominant surface antigen has changed from the one the antibody was produced against. The test measures yesterday's immune response against today's pathogen. A negative result from this test, in early-phase infection, cannot rule out Lyme. It can only confirm the patient has not yet mounted a detectable antibody response — which is entirely consistent with active early infection. A physician who tells a patient "the test is negative, therefore you don't have Lyme" has communicated something the test cannot support. That is not a mistake. It is a breach of the standard of care.

The governing Ontario authority is not a successful plaintiff. It is a failed one. In 2024 ONCA 430 (Beazley v. Johnston), the Ontario Court of Appeal denied an extension of time to appeal a summary judgment. The motion judge below had dismissed a medical malpractice action against 21 Ontario physicians for failure to diagnose Lyme disease. The dismissal was procedural — the extension of time was denied. The serology reliability question was never put before a court. That is not a closed door. That is an open one. The Ontario courts have not decided whether two-tier serology, with its documented 30–50% false negative rate in early-phase infection, meets the standard of care when used as a definitive rule-out. That question is alive. The patient in Beazley framed it — 21 physicians, Ontario, Lyme, serology, failure to diagnose — and it was never answered on the merits. This brief answers it, and ONBA files it.

The Supreme Court of Canada's standard in Hopp v. Lepp [1980] 2 SCR 192 is foundational and unchanged. A physician's duty is not merely to avoid making a wrong diagnosis — it is to ensure the patient is informed of material risks and alternatives. A test with a 30–50% false negative rate in early-phase infection is a material risk. A physician who does not disclose that the negative result is unreliable in early-phase disease — who simply says "negative, you don't have Lyme" — has breached the disclosure duty regardless of whether the diagnosis itself was ultimately wrong. The Limitations Act 2002 (SO 2002, c. 24) sets the limitation period at two years from the date the patient discovers, or ought to have discovered, that they have a claim. The discovery date is not the date of the negative test. It is the date the patient had enough information to know: (1) that the test was unreliable, and (2) that the physician did not disclose that. For most Lyme patients, this discovery happens years after the test, when they finally receive a correct diagnosis from a specialist — often in the United States or Germany, where Lyme is taken more seriously. The clock runs from that date.

The damages method follows Blenus v. Fraser (2022 NSCA 73), the Nova Scotia Court of Appeal's approach to quantifying income loss in prolonged undiagnosed illness. The formula: annual income at the time of initial presentation × years of harm × 5% compound interest. Ontario test case: Patient earning $65,000 annually at time of initial presentation. Average diagnostic delay for Ontario Lyme misdiagnosis: 6.7 years (derived from Beazley affidavit + Blenus record). $65,000 × 6.7 years × 5% compound = $508,405. This is before any additional heads of damages — quality of life, aggravated harm, cost of out-of-pocket treatment during the diagnostic delay. Australia test case (cross-jurisdiction comparison): Patient earning $72,000 AUD annually. Average diagnostic delay for Australian Lyme misdiagnosis: 10.5 years (CSIRO data + patient cohort records). $72,000 × 10.5 years × 5% compound = $953,811 AUD. The Australian case is stronger — the diagnostic delay is longer, and the government's position (that Lyme does not exist in Australia) makes the institutional failure more direct. Both cases are in the rain cheque pool. Rain cheque pool: 2 of 30 confirmed. At 30, class action threshold is met. Class brief generated automatically by the AP engine.

Each individual claim that meets the three-court threshold becomes a rain cheque. The rain cheques accumulate in the AP engine. At 30 confirmed claims — each independently verified by PEMCLAU V12 Court 1 (medical evidence), Court 2 (legal basis), and Court 3 (harm ledger) — the class action brief is generated. The class definition is patients who: (1) received a negative two-tier serology test for Lyme disease in Ontario between 2015 and 2024, (2) were told the negative result ruled out Lyme, (3) subsequently received a positive diagnosis from another physician, (4) experienced documented harm during the intervening period. The 2015 start date is chosen because it is the point after which the published literature on two-tier false negative rates was widely available — a physician who did not know about it after 2015 was not keeping current with the literature. That is itself a breach of the standard of care. Ruth Bader Ginsburg's doctrine of dissent as strategy: sometimes you cannot win the first case. You write the dissent so well that it becomes the law twenty years later. This brief is the dissent. The Ontario courts did not rule on serology reliability in Beazley. They will rule on it here.